Personalis Inc (PSNL) News

Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that a podium talk and multiple abstracts...

Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring

Blood-based assay uses personalized tumor-informed approach designed to detect cancer recurrence early with an ultra-sensitive approach...

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its...

Personalis Reports Fourth Quarter and Full Year 2023 Financial Results

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter...

Form 8-K - Current report

Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its fourth quarter and full year...

Form 4 - Statement of changes in beneficial ownership of securities

Personalis to Participate at Upcoming Investor Conferences

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the...

Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology

Personalis to offer ClearNote’s patented Epigenomic Platform to its biopharmaceutical partners Personalis, Inc. (Nasdaq: PSNL), a leader in...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its...

Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay

NeXT Dx helps clinicians make informed, personalized cancer treatment selections and match patients with clinical trials Access to NeXT Dx...

Form EFFECT - Notice of Effectiveness

Form EFFECT - Notice of Effectiveness

Form 8-K - Current report